Engflag

Carmet

Quick links to important sections

Carmet

Carmet_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carmet

Quick Facts: Carmet Identity

Property Description
Active ingredient Carboxymethylcellulose (Carmellose)
Form Ophthalmic solution (Eye drops)
Pharmacological class Ocular lubricant / Artificial tear
Common use Relieving symptoms of tear film deficiency
Origin Semi-synthetic polymer (derived from cellulose)

What Type of Medicine is Carmet? (Classification and Identity)

Carmet is a trade name for an ophthalmic solution classified as an ocular lubricant and an artificial tear preparation, designed to provide moisture and protection to the eye's surface. It is clinically recognized as a common over-the-counter (OTC) product for treating discomfort related to tear deficiency.

The preparation's activity centers on its single active ingredient, Carboxymethylcellulose, often referred to as Sodium carboxymethylcellulose (NaCMC) or Carmellose. This compound is a semi-synthetic polymeric compound derived and modified from the natural polysaccharide cellulose. Its primary distinction within the artificial tear market is its reputation for superior adherence to the eye's surface, a feature often highlighted in patient information materials.

Composition and General Purpose of Carboxymethylcellulose

The primary function of Carboxymethylcellulose is to act as a viscoelastic agent, increasing the thickness (viscosity) of the liquid administered topically to the eye. This physical property allows the drop to stay on the eye longer than non-viscous liquids.

This specific characteristic enables the formation of a smooth, biocompatible protective layer that adheres to the epithelial surface of the eye. The substance is dissolved in an aqueous solution base, designed for comfortable topical ocular delivery. The compound's properties allow it to maintain hydration and reduce friction. The general purpose of this medicine is therefore to provide sustained lubrication and continuous hydration to the eye, offering relief from the characteristic scratchiness and irritation associated with chronic dry eye symptoms.

Regulatory References

  1. Carboxymethylcellulose Ophthalmic Solution OTC Drug Label (DailyMed)

What side effects are possible with Carmet?

Possible Side Effects and Safety Information

The safety characteristics of Carboxymethylcellulose ophthalmic solution (Carmet) are overwhelmingly local, reflecting the medicine's topical application and negligible systemic absorption. The official regulatory profile identifies potential adverse reactions and safety restrictions that users should be aware of.

Adverse Reaction Scope

The most frequently documented side effects fall under Eye Disorders and are generally classified as Common in regulatory documents. These include local reactions such as eye irritation, eye pain, eye pruritus (itching), and transient blurred vision, often occurring immediately after instillation.

Classification Examples of Officially Listed Adverse Reactions
Common Eye irritation, Eye pain, Eye pruritus, Visual disturbance (blurred vision)
Immune System Hypersensitivity reactions (e.g., eye swelling, allergy)

Serious Adverse Reactions and Safety Restrictions

While serious systemic reactions are rare, regulatory labels identify specific criteria for ceasing use of the product. The medicine must be discontinued if a user experiences a change in vision, persistent eye pain, or if redness and irritation continue or worsen for more than 72 hours, as these symptoms may signal a serious underlying ocular condition. Hypersensitivity reactions, although rare, represent the most clinically significant safety event and serve as a core contraindication; the medicine should not be used by individuals with a known allergy to Carboxymethylcellulose or any listed inactive ingredient. Due to its topical action, specific dosage adjustments for populations with renal or hepatic impairment are generally not required or documented in official labeling. Safety information for use during pregnancy or lactation is often based on the limited systemic exposure.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Carmet ophthalmic solution distinguishes between administration via the eye (the intended route) and accidental ingestion (the non-intended route).

Topical Ocular Overdose Risk

An accidental overdose resulting from the application of excessive eye drops will present no hazard. This finding is consistently documented in regulatory information and is related to the active ingredient, Carboxymethylcellulose, which is a non-systemically absorbed polymer. Because of the negligible systemic exposure and the lack of pharmacological activity, topical use of drops beyond the recommended amount does not result in systemic toxicity or documented clinical signs. Therefore, no specific symptoms or complications are listed for excessive drops administered to the eye.

Emergency Action and Accidental Ingestion

The only condition that mandates an immediate emergency response is the accidental swallowing of the solution. Regulatory labeling requires that if this product is swallowed, a person must get medical help or contact a Poison Control Center right away. There is no specific antidote documented in official prescribing information for this compound. Due to the ingestion hazard, it is officially mandated to Keep out of reach of children, making accidental ingestion in the pediatric population the key consideration for seeking urgent medical attention.

Therapeutic Uses of Carmet

The core therapeutic scope of Carmet is to provide external lubrication to alleviate the distressing symptoms associated with inadequate natural tear production and surface irritation.

Carboxymethylcellulose functions as an eye lubricant used for the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun, and may be used as a protectant against further irritation.

What Carmet Treats: Main Uses and Benefits

The medicine is relevant for addressing tear film deficiency and symptoms of Dry Eye Syndrome (DES), including the common distressing symptoms of burning, stinging, grittiness, and a foreign body sensation. It is applied across domains where additional symptomatic support is needed, such as during periods of environmental exposure (wind, air conditioning) or prolonged visual tasks (computer use). The medicine plays a role in managing specific, distressing symptoms of frictional discomfort.

“Carmet is commonly used to help manage symptoms that become more disruptive during flare-ups and to support general well-being during symptomatic phases.”

This application contributes to maintaining a sense of stability when symptoms are more noticeable, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Support for Dry Eye Symptoms
Primary Indication Tear film deficiency; Dry Eye Syndrome (DES)
Symptom Cluster Burning, stinging, grittiness, and foreign body sensation
Use Context Environmental exposure and visual strain
Symptomatic Focus Supports symptom management and day-to-day comfort

Regulatory References

  1. DailyMed Label: CARBOXYMETHYLCELLULOSE SODIUM solution

Eligibility and Restrictions for Use

The following eligibility rules are based on the official governmental regulatory profile for Carboxymethylcellulose Sodium Ophthalmic Solution, the active ingredient in Carmet.

Eligibility Scope

Classification Eligibility Statement (Official Regulatory Basis)
Populations for whom use is contraindicated Individuals with a documented allergy or known hypersensitivity to Carboxymethylcellulose sodium or any other excipient contained in the specific product formulation.
Populations for whom use is restricted Use is prohibited while wearing contact lenses, as the lenses must be removed prior to administration. Use is also restricted if the solution has changed color or appears cloudy.
Mandatory Discontinuation Use must be stopped immediately and a physician consulted if the patient experiences eye pain, changes in vision, continued redness or irritation of the eye, or if the eye condition worsens or persists for more than 72 hours.
Age-related eligibility rules No specific age restrictions are listed in the regulatory labeling for this over-the-counter ophthalmic drug class.
Pregnancy and Lactation Official labeling does not contain an explicit contraindication; however, women who are pregnant or breastfeeding should consult a healthcare provider before use.

These constraints define the regulatory eligibility profile by establishing an absolute contraindication for hypersensitivity to components and outlining non-negotiable stop-use conditions related to the eye's immediate adverse response, such as pain or persistent irritation, which exclude the patient from continued self-treatment.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Carmet

Interaction Scope

Category Official Regulatory Information for Carmet (Carboxymethylcellulose Ophthalmic Solution)
Medicinal product categories with documented interactions: Other topical ophthalmic solutions (eye drops).
Specific interacting medicines (if explicitly listed): None are individually listed; the constraint applies to the class of other topically applied eye treatments.
Mechanistic basis of interactions (only if stated in label): Physical interference: The solution's viscosity may interfere with the adherence and absorption of subsequently administered ophthalmic products.
Timing-based interaction rules (if applicable): A mandatory separation interval is required when using other topical ophthalmic products; Carmet must be administered last.
Population-specific interaction notes (if applicable): None documented.
Interaction-related restrictions: Administration must be separated in time from other eye drops. No restrictions are documented for systemic drug co-administration, food, alcohol, or herbal products.

Interaction Classifications (High-level)

Classification Official Regulatory Information
Interaction severity classification (as defined in official documents): Relevant local interaction (timing-based constraint). No systemic interactions are documented.
Regulatory basis (EMA / FDA / etc.): FDA / NIH DailyMed Labeling.
Interaction-context constraints (as defined in official documents): Interaction is limited to co-administration with other locally applied eye products; systemic agents, food, and alcohol do not require interaction-related constraints.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with other topical ophthalmic products requires a mandatory time separation to prevent physical interference.
  • The product must be administered last following the use of any other eye drops.
  • No systemic pharmacokinetic or pharmacodynamic interactions are documented, consistent with the product's negligible systemic exposure.

Connection to the overall interaction profile (2–4 sentences): The official regulatory documentation defines Carmet's interaction profile by its sole constraint: a crucial timing rule for co-administration with other topical eye treatments. This constraint is officially stated to prevent the viscous solution from interfering with the application or absorption of subsequent ophthalmic preparations. The labeling confirms the absence of documented systemic interactions, including those involving metabolism, food, or alcohol.

Mechanism of Action

Carmet functions via a dual-action mechanism targeting the molecular regulation of bone remodeling. The active compound is a high-affinity ligand for the X-receptor (XR) on the osteoblast lineage, inducing phosphorylation of the downstream Z-protein, which upregulates transcription factors A and B. This signaling cascade interacts with cell signaling pathways that modulate osteoblast activity.

Simultaneously, Carmet modulates the Receptor Activator of Nuclear factor Kappa-B Ligand/Osteoprotegerin (RANKL/OPG) axis by selectively increasing OPG secretion from stromal cells. The increase in the OPG:RANKL ratio inhibits the binding of RANKL to its receptor on pre-osteoclasts. This blockade restricts the activation and differentiation of osteoclast precursors into mature, bone-resorbing cells.

By modulating the ratio of bone formation to bone resorption, Carmet shifts net bone remodeling toward an anabolic state. This dual-action mechanism includes the modulation of both osteoblast and osteoclast activity. The net result of increased bone formation and decreased bone resorption is a predicted augmentation of bone mineral mass.

Dosage and Administration Information

How to Use Carmet: Administration Guidelines

The administration of Carmet follows a protocol designed to ensure the medicine is taken correctly for its use in adults. Carmet is an oral medication and requires a phased dosing approach.

Administration Details

Guideline Instruction
Route & Preparation Take the tablet by mouth (oral). The tablet must be swallowed whole and must not be crushed, cut, or chewed.
Timing The medicine must be taken with food.
Dosing Frequency The dose is taken once daily.

Dosage and Procedure

Therapy is initiated at a starting dose of X mg once daily. This dose is maintained for Z week(s), followed by an increase to Y mg once daily, provided the initial dose was tolerated. This process is known as titration and is essential for establishing the appropriate maintenance dose.

Procedural Conditions:

  • Health Status Check: Before and during treatment, specific laboratory assessments, such as renal function testing, are required to determine the patient's capacity to safely receive and process the medicine.
  • Missed Dose: If a daily dose is forgotten, the instruction is to skip the missed dose completely. The patient must then take the next scheduled dose at the usual time and must not take two doses at once to compensate for the missed dose.
  • Age-Group: Carmet is for use in adult patients only.

These administration instructions establish a defined, step-by-step protocol: first, a health check to confirm patient eligibility; second, a defined low-dose initiation; and third, a gradual, time-based dose increase. This structure ensures a standardized approach to medication use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Carmet

Overview of Studies for Dry Eye Syndrome and Tear Film Deficiency

The core research for Carmet (carboxymethylcellulose) focuses on patients experiencing symptoms associated with Dry Eye Syndrome (DES) and tear film deficiency. These conditions were studied in research exploring short-term symptom changes. The evidence base consists primarily of short-term randomized controlled trials (RCTs), systematic reviews, and observational studies that monitored the solution in studies where the focus was surface moisture and discomfort.

Research evaluated patient-reported outcomes describing perceived discomfort in adult patients with mild to moderate dry eye. Alongside these subjective measures, researchers monitored objective clinical signs, including the stability of the natural tear film (Tear Break-Up Time or TBUT) and the integrity of the ocular surface, which was observed in controlled trials. The findings describe patterns observed in the studies over short periods. However, findings across the broad evidence landscape have sometimes been mixed or heterogeneous when comparing different artificial tear products. Overall, certainty can be low for definitive conclusions across all possible dry eye presentations.

Extended Follow-up and Long-Term Research

The evidence base largely consists of research exploring short-term symptom changes over defined time intervals. Long-term effects are not fully established. Follow-up durations were limited in many of the core randomized trials, often lasting only a few weeks to three months.

As a result, there is limited information for long-term outcomes regarding the durability of the initial changes observed when the solution is used over many years. Researchers have not consistently published data that tracks how use of the solution may relate to chronic symptom patterns over periods exceeding six months. The evidence contributes to the broader evidence landscape by describing short-term patterns, but it does not determine long-term outcomes.

Evidence Gaps and Research Uncertainty

Data for certain groups remain insufficient in the published literature. Most core trials were evaluated in general adult populations with mild-to-moderate DES. There is limited information regarding specific subgroups, such as the elderly, patients with different systemic comorbid conditions, or individuals with severe, chronic dry eye manifestations. Furthermore, specific trials dedicated to studying the use of Carmet in pediatric populations (children) are lacking. Research describes short-term symptomatic change but is still uncertain about the outcomes over extended periods of use.

Key Studies & References

  1. Carboxymethylcellulose Sodium Ophthalmic Solution 0.5% (preservative free) Lubricant Eye Drops - DailyMed (FDA Labeling)

Frequently Asked Questions (FAQ)

Common questions about Carmet (FAQ)

Q: Can children or teenagers use these eye drops?

Official regulatory documents and research overviews generally state that specific data for use in pediatric populations, which includes children and teenagers, may not be available. Official documents recommend consulting a healthcare provider for specific guidance on use in these age groups.

Q: Is there any issue with taking Carmet if I am pregnant or breastfeeding?

According to the official product information, there is no explicit contraindication for use during pregnancy or breastfeeding. Official labeling states that women who are pregnant or breastfeeding should consult a healthcare provider before use.

Q: Does Carmet interact with any oral medications, food, or alcohol?

No systemic interactions are documented in the official regulatory product labeling for Carmet. This means there are no documented constraints or warnings regarding co-administration with oral medicines, food, or alcohol.

Q: Do I need to take out my contact lenses before I use Carmet?

Official regulatory information states that contact lenses must be removed prior to the administration of the eye drops. The product labeling provides instructions regarding when contact lenses may be reinserted.

Q: Where does Carmet work on the eye to stop the irritation?

Carmet is classified as an ocular lubricant, which means it works topically on the surface of the eye. Its active ingredient, Carboxymethylcellulose, is a viscoelastic agent that forms a smooth, protective layer over the epithelial surface to maintain hydration and reduce friction.

How should Carmet be stored and disposed of?

How to Store and Dispose of Carmet?

Carmet (Carboxymethylcellulose ophthalmic solution) must be stored at Controlled Room Temperature, generally between 15°C and 30°C (59°F and 86°F), and certain formulations must be protected from light. The medicine must be kept out of the sight and reach of children.

Stability and Disposal

To prevent contamination, single-dose containers must be used immediately after opening and then discarded. Multi-dose bottles may have a discard period, often one month after opening. Do not use the solution if it becomes cloudy or the seal is broken. Disposal of unused or expired product must be done in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Carmet found in:

A-Z Index: